Clobetasol (0.05% w/w) + Gentamicin (0.1% w/w) + Clioquinol (Iodochlorhydroxyquin) (1% w/w) + Ketoconazole (1% w/w) + Tolnaftate (1% w/w) (Medical Monograph)

Overview

A potent, broad-spectrum, fixed-dose combination topical preparation designed for the treatment of complex, mixed, or secondarily infected inflammatory dermatoses, particularly those involving fungal and bacterial components. It combines a super-high-potency corticosteroid (Clobetasol) with an aminoglycoside antibiotic (Gentamicin), an antifungal with antibacterial/antiprotozoal properties (Clioquinol), a broad-spectrum imidazole antifungal (Ketoconazole), and an allylamine antifungal (Tolnaftate). This combination is intended to address inflammation, bacterial infection, and a wide range of fungal pathogens (dermatophytes, yeasts, molds) simultaneously.

This combination exerts a multifaceted action: 1) Clobetasol: Potent anti-inflammatory, immunosuppressive, antiproliferative, and vasoconstrictive effects by binding to glucocorticoid receptors, inhibiting inflammatory mediators (prostaglandins, leukotrienes), and suppressing lymphocyte activity. 2) Gentamicin: Bactericidal action against Gram-negative and some Gram-positive bacteria by binding to the 30S ribosomal subunit, inhibiting protein synthesis. 3) Clioquinol: Exerts antifungal and antibacterial action, likely through chelation of essential metal ions (e.g., Fe, Cu) required for microbial enzyme function. 4) Ketoconazole: Inhibits fungal ergosterol synthesis by blocking the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, damaging the fungal cell membrane. 5) Tolnaftate: Disrupts fungal hyphal growth and mycelial development, possibly by inhibiting squalene epoxidase, leading to ergosterol deficiency and accumulation of squalene.